天眼查商业履历信息显示，浙江和仁科技股份有限公司，成立于2010年，位于杭州市，是一家以从事软 件和信息技术服务业为主的企业。企业注册资本26256.0141万人民币，实缴资本6000万人民币。公司法 定代表人为赵晨晖。 通过天眼查大数据分析，浙江和仁科技股份有限公司共对外投资了26家企业，参与招投标项目1015次， 知识产权方面有商标信息154条，专利信息17条，此外企业还拥有行政许可115个。 金融界消息 截至2025年8月12日收盘，和仁科技（300550）报收于13.66元，下跌1.09%，换手率 1.56%，成交量4.10万手，成交金额5608.29万元。 资金流向方面，今日主力资金净流出1212.02万元，占比成交额21.61%。其中，超大单净流出755.12万 元、占成交额13.46%，大单净流出456.90万元、占成交额8.15%，中单净流出流入252.57万元、占成交 额4.5%，小单净流入959.45万元、占成交额17.11%。 和仁科技最新一期业绩显示，截至2025一季报，公司营业总收入7839.61万元、同比减少13.99%，归属 净利润384.41万元，同比减少645.00%，扣非净 ...

| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-08 | 13.48 | -2.53% | -1303.71万 | -15.36% | 1051.85万 | 12.39% | 251.86万 | 2.97% | | 2025-08-07 | 13.83 | -1.78% | -327.81万 | -5.97% | 33.37万 | 0.61% | 294.44万 | 5.36% | | 2025-08-06 | 14.08 | 1.81% | -4.07万 | -0.06% | -234.97万 | -3.24% | 239.04万 | 3.29% | | 2025-08-05 | 13.83 | 0.44% | -748.00万 | -14.53% | 660.71万 | 12.84% | 87.30万 | 1.70% | | 2025-08-04 | 13.77 -0.07% | | -531.83万 ...

Core Viewpoint - He Ren Technology has been penalized for the improper use of idle raised funds, leading to a warning letter from the Zhejiang Securities Regulatory Bureau, which will impact the company's future financing and mergers [1][2]. Group 1: Violation Details - He Ren Technology used 400.91 million yuan of idle raised funds for cash management, exceeding the board-approved limit of 250 million yuan [2]. - The company failed to conduct necessary internal review procedures and did not disclose the violation in a timely manner, only addressing it nearly 11 months later [2][4]. - The violations include exceeding the board's authorization, failing to submit significant fund operations for board review, and not disclosing important matters within two trading days [3][4]. Group 2: Consequences of the Warning Letter - The warning letter serves as a regulatory "yellow card," affecting He Ren Technology and its executives in future financing, mergers, and other significant matters [5]. - The company and its executives will face increased scrutiny from regulatory bodies, which may require additional disclosures or extended review periods for future transactions [5]. - The executives involved, including the chairman and CFO, may experience long-term impacts on their professional reputations and career opportunities in the capital market [5]. Group 3: Historical Context - He Ren Technology has a history of regulatory issues, having been criticized by the Shenzhen Stock Exchange in 2023 for failing to timely announce a significant annual loss of over 83.3 million yuan [6]. - The company reported a net loss of 38.44 million yuan in Q1 2025, which is an increase in losses compared to the previous year [6].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhejiang Heren Technology Co., Ltd., which closed at 13.49 yuan with a PE ratio of 98.47 times, while the industry average PE is 120.22 times [1][2] - The company's total market capitalization is 3.542 billion yuan, ranking 144th in the software development industry based on PE ratio [1][2] - The company experienced a net outflow of 1.0375 million yuan in principal funds on July 8, but had a total inflow of 2.5346 million yuan over the past five days [1] Group 2 - Heren Technology's main business involves the research, sales, implementation integration, service support, and solution provision for clinical medical information systems and digital application systems [1] - The latest financial report for Q1 2025 shows the company achieved operating revenue of 78.3961 million yuan, a year-on-year decrease of 13.99%, and a net profit loss of 3.844103 million yuan, a year-on-year decline of 645.00% [1] - The company's gross profit margin stands at 32.76% [1]

一、警示函的主要内容 浙江证监局在日常监管中发现，和仁科技于 2024 年 5 月 23 日使用部分闲置 募集资金进行现金管理，合计金额 40,091.44 万元，超出前期董事会审议的 25,000 万元闲置募集资金现金管理限额。公司未就上述事项及时履行审议程序 和信息披露义务，直至 2025 年 4 月 22 日才召开董事会会议补充审议并披露。 公司上述行为违反了《上市公司监管指引第 2 号—上市公司募集资金管理和 使用的监管要求》(证监会公告〔2022〕15 号)第八条和《上市公司信息披露管 理办法》(证监会令第 182 号)第三条的规定。公司董事长兼总经理赵晨晖、董事 会秘书章逸、财务负责人刘双双违反了《上市公司信息披露管理办法》(证监会 令第 182 号)第四条和第五十一条规定，对上述违规行为承担主要责任。 根据《上市公司信息披露管理办法》(证监会令第 182 号)第五十二条规定， 浙江证监局决定对公司、赵晨晖、章逸、刘双双分别采取出具警示函的监督管理 措施，并记入证券期货市场诚信档案。你们应充分吸取教训，加强相关法律法规 学习，提高规范运作意识，杜绝类似情况再次发生，并于收到本决定书之日起 10 个 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of HeRen Technology, indicating a significant decline in revenue and profit for Q1 2025 compared to the previous year [1][2] - HeRen Technology's stock closed at 13.43 yuan, with a PE ratio of 98.03, which is below the industry average of 117.07 and the median of 85.14 [1][2] - The company has a total market capitalization of 3.526 billion yuan, ranking 146th in the software development industry based on PE ratio [1][2] Group 2 - As of Q1 2025, five institutions hold shares in HeRen Technology, with a total of 13.85358 million shares valued at 1.818 billion yuan [1] - The company's main business involves the research, sales, implementation, and support of clinical medical information systems and digital application systems [1] - The latest financial report shows a revenue of 78.3961 million yuan, a year-on-year decrease of 13.99%, and a net profit loss of 3.844103 million yuan, reflecting a 645% decline [1]

Core Viewpoint - The digital hospital industry in China is experiencing rapid growth, with the market size expected to reach 487.7 billion yuan in 2024 and 525 billion yuan in 2025, driven by advancements in technology and the need for modernization in healthcare [1][4][6]. Digital Hospital Industry Definition and Classification - Digital hospitals utilize advanced computer network systems to integrate patient diagnosis, health economic information, and hospital management data into a comprehensive information management system [2][4]. - Key products in the digital hospital industry include Hospital Information Systems (HIS), Clinical Information Systems (CIS), Picture Archiving and Communication Systems (PACS), Laboratory Information Systems (LIS), and Electronic Medical Records (EMR) [2]. Current Development Status of the Digital Hospital Industry - The digital hospital market in China has grown from 18.2 billion yuan in 2014 to 487.7 billion yuan in 2024, with projections for 2025 indicating further growth [4][6]. - The digital transformation of hospitals is essential for adapting to societal changes and improving operational efficiency [4][6]. Industry Structure and Value Chain - The digital hospital industry value chain includes upstream technology and equipment suppliers, midstream solution integrators, and downstream hospitals [8]. - The application of digital solutions in hospitals is expanding, enhancing operational efficiency and service delivery [8]. Development Environment and Relevant Policies - The Chinese government has implemented various policies to support the digital transformation of hospitals, emphasizing the need for electronic medical records and health information sharing [10][12]. - Key policies include the promotion of smart hospitals and the integration of health information systems across regions [10][12]. Competitive Landscape of the Digital Hospital Industry - The market features both domestic and international players, with major companies including Microsoft, Cisco, IBM, and domestic firms like Eastsoft, Founder, Huawei, and others [13][15]. - Domestic companies are increasingly gaining market share, focusing on providing comprehensive digital solutions for hospitals [13][15]. Key Companies in the Digital Hospital Industry - Eastsoft has over 300 proprietary products and provides comprehensive information solutions for hospitals, with projected revenues of 13.32 billion yuan in 2024 [15]. - Chuangyue Huikang has implemented over 10,000 healthcare information projects and serves more than 7,000 clients, with revenues of 1.423 billion yuan in 2024 [17]. Implementation Pathways for Digital Transformation - The digital transformation of hospitals requires top-level design, scientific data management, and strengthening of academic disciplines to enhance information management capabilities [19][21][22]. - Emphasis on cross-disciplinary collaboration and talent development is crucial for achieving sustainable growth in hospital information management [22][23].

一、股东大会审议通过利润分配方案的情况 证券代码：300550 证券简称：和仁科技 公告编号：2025-020 浙江和仁科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司 2024 年年度权益分派方案为： 以公司现有总股本 262,560,141 股为基数，向全体股东每 10 股派 0.250000 元人民币现金（含税；扣税后，境外机构（含 QFII、RQFII）以及持有首发前限 售股的个人和证券投资基金每 10 股派 0.225000 元；持有首发后限售股、股权激 励限售股及无限售流通股的个人股息红利税实行差别化税率征收，本公司暂不扣 缴个人所得税，待个人转让股票时，根据其持股期限计算应纳税额【注】；持有首 发后限售股、股权激励限售股及无限售流通股的证券投资基金所涉红利税，对香 港投资者持有基金份额部分按 10%征收，对内地投资者持有基金份额部分实行差 别化税率征收）， 【注：根据先进先出的原则，以投资者证券账户为单位计算持股期限，持股 1 个月（含 1 个月）以 内， 每 10 股补缴税款 0.050000 元；持股 1 个月以上至 ...

证券代码：300550 证券简称：和仁科技 公告编号：2025-020 浙江和仁科技股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东大会审议通过利润分配方案的情况 1、浙江和仁科技股份有限公司（以下简称"公司"或"本公司"）2024 年 年度权益分派实施方案已获 2025 年 5 月 14 日召开的 2024 年年度股东大会审议 通过，股东大会审议通过的分配方案具体内容为：以未来实施 2024 年年度权益 分配方案时股权登记日享有利润分配、公积金转增股本权利的总股本为基数，向 全体股东每 10 股派发现金红利 0.25 元（含税），不送红股，不以资本公积转增 股本。若利润分配方案实施完毕前，公司股本发生变动，公司将维持每股分配比 例不变，相应调整分配总额。 以公司现有总股本 262,560,141 股为基数，向全体股东每 10 股派 0.250000 元人民币现金（含税；扣税后，境外机构（含 QFII、RQFII）以及持有首发前限 售股的个人和证券投资基金每 10 股派 0.225000 元；持有首发后限售 ...

证券代码：300550 证券简称：和仁科技 公告编号：2025-019 浙江和仁科技股份有限公司 关于已披露日常经营合同签订正式合同的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江和仁科技股份有限公司（以下简称"和仁科技"或"公司"）分别于 2025 年 4 月 7 日和 2025 年 4 月 10 日披露了《关于日常经营合同预中标的提示性公告》 《关于已披露日常经营合同收到中标通知书的进展公告》（详见巨潮资讯网 http://www.cninfo.com.cn，公告编号：2025-001；2025-002），公司近日收到 与新疆维吾尔自治区中医医院签署的正式合同及补充协议，具体情况如下： 一、特别提示 1、合同生效条件：经双方法定代表人或授权委托代表人签字并加盖单位公 章后生效。 2、合同的履行对公司的影响：若合同顺利实施，将对公司 2025 年度经营业 绩产生积极的影响。 3、合同的重大风险及重大不确定性：本合同在履行过程中，存在因市场环 境、宏观经济以及其他不可抗力因素发生重大变化而导致合同无法履行的风险。 敬请广大投资者注意投资风险。 ...